These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 25538019)

  • 41. Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.
    Ogawa K; Ito Y; Hirokawa N; Shibuya K; Kokubo M; Ogo E; Shibuya H; Saito T; Onishi H; Karasawa K; Nemoto K; Nishimura Y;
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):559-65. PubMed ID: 22019243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
    Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins.
    Rwigema JC; Heron DE; Parikh SD; Zeh HJ; Moser JA; Bahary N; Ashby K; Burton SA
    J Gastrointest Cancer; 2012 Mar; 43(1):70-6. PubMed ID: 20809393
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study.
    Comito T; Cozzi L; Clerici E; Franzese C; Tozzi A; Iftode C; Navarria P; D'Agostino G; Rimassa L; Carnaghi C; Personeni N; Tronconi MC; De Rose F; Franceschini D; Ascolese AM; Fogliata A; Tomatis S; Santoro A; Zerbi A; Scorsetti M
    Technol Cancer Res Treat; 2017 Jun; 16(3):295-301. PubMed ID: 27311310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer.
    Lischalk JW; Burke A; Chew J; Elledge C; Gurka M; Marshall J; Pishvaian M; Collins S; Unger K
    J Gastrointest Cancer; 2018 Jun; 49(2):116-123. PubMed ID: 28044263
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer: A single center experience.
    Jumeau R; Delouya G; Roberge D; Donath D; Béliveau-Nadeau D; Campeau MP
    Dig Liver Dis; 2018 Apr; 50(4):396-400. PubMed ID: 29326012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
    Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.
    Hurt CN; Falk S; Crosby T; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T; Mukherjee S
    Br J Cancer; 2017 May; 116(10):1264-1270. PubMed ID: 28376080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
    Varadhachary GR; Wolff RA; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Abdalla E; Wang H; Staerkel GA; Lee JH; Ross WA; Tamm EP; Bhosale PR; Krishnan S; Das P; Ho L; Xiong H; Abbruzzese JL; Evans DB
    J Clin Oncol; 2008 Jul; 26(21):3487-95. PubMed ID: 18640929
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
    Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma.
    Quan K; Sutera P; Xu K; Bernard ME; Burton SA; Wegner RE; Zeh H; Bahary N; Stoller R; Heron DE
    Pract Radiat Oncol; 2018; 8(2):95-106. PubMed ID: 29291966
    [TBL] [Abstract][Full Text] [Related]  

  • 53. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
    World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1).
    Arcelli A; Buwenge M; Macchia G; Bertini F; Guido A; Deodato F; Cilla S; Scotti V; Rosetto ME; Djan I; Parisi S; Mattiucci GC; Cellini F; Fiore M; Bonomo P; Belgioia L; Niespolo RM; Gabriele P; Di Marco M; Simoni N; Mazzarotto R; Morganti AG;
    Cancer Med; 2020 Nov; 9(21):7879-7887. PubMed ID: 32910549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
    Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC
    Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.
    Marti JL; Hochster HS; Hiotis SP; Donahue B; Ryan T; Newman E
    Ann Surg Oncol; 2008 Dec; 15(12):3521-31. PubMed ID: 18830756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.
    Sherman WH; Hecht E; Leung D; Chu K
    Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.
    Serrano PE; Herman JM; Griffith KA; Zalupski MM; Kim EJ; Bekaii-Saab TS; Ben-Josef E; Dawson LA; Ringash J; Wei AC
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):270-7. PubMed ID: 25104069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.
    Chauffert B; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L
    Ann Oncol; 2008 Sep; 19(9):1592-9. PubMed ID: 18467316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma.
    Simoni N; Micera R; Paiella S; Guariglia S; Zivelonghi E; Malleo G; Rossi G; Addari L; Giuliani T; Pollini T; Cavedon C; Salvia R; Milella M; Bassi C; Mazzarotto R
    Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):e31-e38. PubMed ID: 32682686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.